Which statement best describes the routine monitoring for clozapine use?

• A. Routine monitoring recommendation
• B. Imaging every 6 months
• C. No monitoring required
• D. Monthly liver function tests

Answer: (C)

Clozapine safety hinges on ongoing laboratory monitoring because of the risk of agranulocytosis and metabolic side effects. The essential routine checks are regular hematologic surveillance (white blood cell count and absolute neutrophil count) and periodic metabolic monitoring, with clinical assessment. Imaging studies are not a standard part of routine clozapine monitoring, and liver function tests are not routinely required solely because a patient is on clozapine unless clinically indicated. Therefore, the statement that no monitoring is required does not align with established safety practices. The important concept to study is that clozapine requires ongoing, systematic safety monitoring rather than no monitoring at all.